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Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked enzymopathy that affects hundreds
of millions of people worldwide, conferring increased risk of neonatal jaundice and oxidant-induced
hemolytic anemia. Screening and diagnosis of G6PD deficiency is currently performed using genetic or
biochemical assays, the former being cost ineffective in populations with significant allelic heterogeneity,
and the latter being limited in ability to detect female heterozygotes. Cytochemical assays can obviate these
shortcomings, but at the expense of added technical complexity and labor. We describe here a simple, novel
cytofluorometricmethodthatextendstheclassicmethemoglobinreductiontest,assessingG6PDdeficiency
at the level of an individual erythrocyte. In preliminary testing in Malian children, there was strong
concordance between our method and established genetic and biochemical techniques. The assay is robust
and economical, and could serve as a screening method as well as a research tool, especially for
high-throughput applications such as flow cytometry.
G
lucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme that catalyses the rate-limiting
first step in the pentose phosphate pathway, where it produces nicotinamide adenine dinucleotide
phosphate (NADPH), a critical cofactor in a variety of metabolic processes. In the red blood cell
(RBC), G6PD activity is especially important as the principal source of reducing power to regenerate the anti-
oxidantglutathione.IndividualswithG6PD-deficientRBCsarethusatriskforhemolysisprecipitatedbyoxidants
found in certain foods or chemotherapeutics, or generated during severe infections. One especially important
example of drug-induced hemolysis is that caused by primaquine
1–3, one of few antimalarial drugs active against
both Plasmodium vivax hypnozoites and P. falciparum gametocytes. As areas of high malaria transmission
overlap geographically with areas of high G6PD deficiency prevalence, this drug sensitivity reaction is
an important public health concern, especially given recent interest in reducing and eliminating malaria
transmission
4,5.
Despitedecadesofresearch,ourunderstandingofthemolecularpathogenesisofG6PDdeficiencyintheRBCis
incomplete. While many functional allelic variants of G6PD have been described, it is less well understood how
this genetic heterogeneity translates into diversity at the level of molecular and clinical phenotypes. Since clinical
phenotypessuchasprimaquinesensitivityandmalariaprotectionarecomplexandmultifactorialinetiology,itis
critical that the more proximate link between genetics and molecular phenotypes be clearly elucidated. This
objective will require the development of novel methodologies suitable for high-throughput work.
One fundamental molecular phenotype to consider is G6PD enzyme activity, not only at the level of a single
RBCbutalsoinapopulationofRBCs.Whilemanysevere,sporadicG6PDvariantsaredefectiveintheirabilityto
form active dimers and tetramers, the means by which the most common variants, such as the main African
variant‘G6PDA-’,aredeficient inenzymeactivityarepoorlyunderstood.Asthecatalyticrateofthesevariantsis
minimal, it is believed that the G6PD deficiency phenotypes they produce may result from decreased thermal
stability of the protein
6,7. According to this theory, nascent RBCs emerge from the bone marrow invested with
near-normal G6PD activity in deficient individuals and the RBC aging process leads to a rapid decrease in the
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8. As many factors influence RBC
senescence, it is also important to think of G6PD enzyme deficiency
as a population characteristic, dependent on the age distribution of
RBCs, where a significant proportion of reticulocytes can impact the
measurement of G6PD enzyme activity in hemolysates.
InfemalesthatareheterozygousforG6PDdeficiencypolymorph-
isms, the picture of cell population variation is even more compli-
cated due to the random X-chromosome inactivation that produces
a mosaic population of G6PD-normal and G6PD-deficient RBCs.
Selection processes during or shortly after hematopoiesis, or skewed
patterns of X-chromosome inactivation
9, which itself may be influ-
encedbyage
10,eachhavethepotentialtosignificantlyaltertheG6PD
deficiency status in a female heterozygote.
Various methods have been developed for assessing an indivi-
dual’s G6PD activity status, and these can be loosely grouped into
genetic, gross biochemical, and cytochemical approaches.
Genetic typing of G6PD variants has a long history that began
shortly after the development of gel electrophoresis, with variant
G6PD enzymes first identified on the basis of differential migration
rate on starch gels
11. Today, this has been largely superseded by
DNA-basedgenotypingandsequencing,whichenabletheidentifica-
tion of hundreds of nonsynonymous coding mutations associated
with G6PD deficiency worldwide
12, including many region-specific
common variants.
Gross biochemical typing of G6PD involves either direct or indir-
ectmeasuresofenzymeactivityinhemolysates.Directtestsarethose
that assess the enzyme’s production of NADPH, which absorbs
(340 nm) and fluoresces (450 nm) at characteristic wavelengths of
light. These include the quantitative gross activity assay
13, where the
initial reaction velocity of the G6PD reaction is measured by exam-
ining the rate at which NADPH is produced. A qualitative analogue
is the fluorescent spot test
14, a popular screening test in which a drop
of blood incubated with G6PD reaction substrates is placed on filter
paper and illuminated with UV light, where the presence or absence
of fluorescence provides a categorical measure of G6PD activity.
Indirect assays of G6PD activity translate NADPH production into
a colorimetric readout using chromophores like brilliant cresyl
blue
15, resazurin
16, or formazan derivatives
17,18; these assays typically
involve long incubation periods of several hours (it is likely that they
all rely on one or more oxidoreductases with poor kinetic profiles).
One indirect test with shorter incubation times and more consistent
results is the methemoglobin reduction test (MRT), once a widely
used screening tool in resource-poor areas
19,20. In this colorimetric
assay, G6PD activity is assessed by first treating RBCs with nitrite
(converting oxyhemoglobin [red] to methemoglobin [brown]), and
then examining the rate of NADPH-dependent methemoglobin
reduction in the presence of an appropriate redox catalyst (Nile blue
or methylene blue) and substrate (glucose).
Cytochemical typing provides a categorical assessment of G6PD
enzyme activity (i.e., ‘normal’ or ‘deficient’) at the level of an indi-
vidual RBC, and thus is the biochemical technique with greatest
sensitivity for detecting mosaicism in female heterozygotes
21. The
methemoglobin elution test
22, the earliest assay developed, is a light
microscopic technique that extends the aforementioned MRT by
submerging cyanide-treated thin blood smears in an ethanol-based
solution of peroxide and citric acid prior to conventional staining,
with individual RBCs labeled according to their relative methemo-
globin content. Another more recently developed assay detects the
quenching of glutaraldehyde-induced autofluorescence by formazan
crystals produced in cells with normal G6PD activity
23. Owing to
their relative difficulty, technical complexity, and often ambiguous
results
20, neither technique is particularly well suited to high-
throughput applications.
Neither genetic nor gross biochemical approaches capture the
full picture of G6PD activity. While genetic typing offers generally
unequivocal interpretation of results, it is imperfectly predictive of
both molecular and clinical phenotypes. In addition, typing multiple
polymorphisms may not be cost-effective in resource-poor areas of
allelicheterogeneitysuchasWestAfrica,SoutheastAsia,orOceania.
Conversely, while gross biochemical approaches offer a functional
assessment of G6PD deficiency, they are often difficult to interpret,
especially for mosaic female heterozygotes, and insufficiently scal-
able. Cytochemical methods can thus fill a void and, beyond their
utilityasascreening technique, canserveasaresearchtooltounder-
stand how genetic polymorphisms manifest at the level of G6PD
activity in individual RBCs.
A straightforward cytochemical typing assay is presented here,
termed the ‘cytofluorometric method’, which provides a fluoro-
metric readout of the classic MRT at the level of an individual
RBC. Upon testing this method on a cohort of Malian children, it
was found to exhibit strong agreement with established methods of
genetic and gross biochemical typing. This assay represents a useful
addition to the screening and research toolkit for G6PD deficiency,
especially in malaria-endemic areas.
Results
Development of the cytofluorometric method. The cytofluo-
rometric method described here can be considered most simply as
a fluorometric readout of a classic test for G6PD deficiency, the
methemoglobin reduction test (MRT), at the level of an individual
RBC (Figure 1). The MRT is a standard colorimetric test for G6PD
Figure 1 | Principle of the cytofluorometric method. The cytofluorometric method is a fluorometric extension of the methemoglobin reduction test
(left). Fluorescence intensity distributions (FL1, right) show that the sequential reaction of cyanide followed by peroxide in RBCs containing
predominantly oxyhemoglobin yields a fluorescent product (grey), while in nitrite-treated RBCs containing predominantly methemoglobin, little or no
fluorescence is generated (white).
www.nature.com/scientificreports
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19,20. In the first step, RBCs were treated with nitrite to
oxidize all oxyhemoglobin (oxy-Hb, Fe
21) to methemoglobin (met-
Hb, Fe
31). After washing away excess nitrite, glucose (substrate) and
Nile blue sulfate (redox catalyst) were added, driving reduction of
met-Hb back to oxy-Hb via an NADPH-dependent methemoglobin
reductase (NADPH-hemoprotein reductase). The activity of this
enzyme is dependent on NADPH, which is produced in the RBC
solelybyG6PD.Therateofthereductasereactiongenerallyproceeds
slowly, but is enhanced by Nile blue, which acts as an intermediate
electron carrier between NADPH and the reductase. Thus, it is an
indirect assay for G6PD deficiency, as normal RBCs (G6PD1) are
able to quickly reduce met-Hb, while deficient RBCs (G6PD-)
are not. At the end of the incubation period, G6PD1 samples
(containing oxy-Hb) are red, G6PD- samples (containing met-Hb)
are brown, with heterozygous (G6PD1/2) samples exhibiting an
intermediate color. The MRT is sensitive to detection of both mild
(class III, e.g., ‘G6PD A-’) and more severe (class II, e.g., ‘G6PD
Mediterranean’) forms of G6PD deficiency
24,25, presumably
because of a threshold effect where a given level of G6PD activity
is necessary for methemoglobin reduction to proceed at a visually
observable rate within the reaction time allotted.
The cytofluorometric method follows on from the MRT by
sequential reaction of cyanide followed by peroxide to generate a
fluorescent product inside RBCs containing oxy-Hb, but little or
nofluorescence fromthosecontainingmet-Hb.Inthefirststep,only
met-Hb reacts with cyanide to generate cyanmethemoglobin (cyan-
met-Hb), while oxy-Hb remains unreactive
26. In the second step,
only oxy-Hb reacts with peroxide
27,28 to generate a fluorescent prod-
uct (ferryl-Hb), while cyanmet-Hb remains largely nonreactive and
nonfluorescent (Figure 1). After these two reactions, G6PD1 cells
contain brightly fluorescent ferryl-Hb, while G6PD- cells contain
very dimly fluorescent cyanmet-Hb (Figure 2), with fluorescent sig-
naluniformlydistributedthroughoutcells(Figure3).Onecannotsay
with absolute certainty what the fluorescent adduct(s) generated
from these reactions are, but the major component is likely derived
from conversion of ferrous heme to fluorescent iron-free por-
phyrin
29–32, with an additional contribution from lipid peroxidation
products such as malonyldialdehyde
33,34.
Correlation of cytofluorometric data with genotype and gross
activity data. The cytofluorometric method was applied to
peripheral blood samples obtained from 42 healthy Malian
children who were enrolled into a longitudinal cohort study. In
addition, gross measures of G6PD enzyme activity were obtained
using hemolysates derived from the same samples, as was genotype
datafortheG6PD202(‘A-’,rs1050828,C.T,Val68Met)variant,the
most common G6PD deficiency polymorphism in Africa
35. These
latter two ‘gold-standard’ techniques provide a benchmark against
which to evaluate the cytofluorometric method.
Asexpected,therewasastrongrelationshipbetweendataobtained
usingthetwoestablishedtechniques,thegeneticandgrossbiochem-
ical activity assays, with variation in genotype explaining 78% of
variation in gross activity (Figure 4A, P 5 5.5310
214, 1-way
ANOVA). Interestingly, the correlation between genotype and cyto-
fluorometrydatawasevenstronger,withgenotypeexplaining89%of
varianceintheproportionofG6PD1cellsfoundbycytofluorometry
(Figure 4B, P 5 1.0310
221, 1-way ANOVA). Finally, it was found
that the proportion of G6PD1 cells observed by cytofluorometry
was well modeled by gross activity (Figure 4C, Spearman’s rho 5
10.88, P , 2.2310
216) with the relationship remaining significant
when considering only heterozygotes, in whom variance in both
measures is greatest (Spearman’s rho 51 0.65, P 5 0.01).
Afewoutlierswereobservedinthedata,includingtwoindividuals
who had homozygous A1 genotypes at G6PD 202 but exhibited
mosaicism by cytofluorometry (Figure 4B), which may be the result
of other, untyped G6PD deficiency mutations that are present at
lower frequency in West Africa (e.g., G6PD 542, 680, or 968). The
lone heterozygous outlier (Figure 4B) illustrates the difficulty of
detecting certain mosaic females who seem to have normal enzyme
activity, a well-documented limitation of the MRT
22. Interestingly,
A- males still exhibited a significant population of G6PD1 RBCs,
which likely reflects the younger population of RBCs (likely reticu-
locytes) in which G6PD enzyme activity has not yet declined signifi-
cantly.
Discussion
The cytofluorometric method described here is a new approach for
typing G6PD deficiency at the level of individual RBCs. It provides a
fluorescent readout of an established screening method (i.e., the
methemoglobin reduction test, MRT) for G6PD deficiency, utilizing
the unique redox chemistry and abundance of hemoglobin in the
RBCtogenerateadifferentialauto-fluorescentsignalthatadequately
distinguishes G6PD-normal from G6PD-deficient RBCs. In prelim-
inary testing in Malian children, this assay showedstrong agreement
withotherestablishedmethodsoftypingG6PDdeficiency,including
genotyping and gross biochemical activity. Additionally, it has
performance characteristics that make it useful for clinicians and
researchers alike, especially in resource-poor settings.
The literature suggests different possibilities for the origin of the
fluorescent signal created when hydrogen peroxide reacts with oxy-
hemoglobin. Since this peroxide reaction does not occur with cyan-
methemoglobin, it seems likely that the major fluorescent adduct
created is a protoporphyrin derivative
29–32 generated from ferryl
heme (Fe
41) created as a result of the reaction of peroxide with
ferrous heme (Fe
21). Another possible component of the fluorescent
signal may derive from lipid peroxidation
33,34, involving fatty acid
derivatives such as malonyldialdehyde (MDA). Since MDA genera-
tionhasbeen showntobeprecipitated byunstable hemoglobins,itis
possible that there is a complicated and co-dependent relationship
between porphyrin generation and any downstream adducts such as
those from lipid peroxidation
32,36.
Severalquestionsemergingfromthisworkconcernthemethemo-
globin reduction test, upon which the cytofluorometric method is
dependent. One issue involves the potential forheritable variation in
Figure 2 | Demonstrationofthecytofluorometric methodonartificialmixturesofA1andA2RBCs. Fluorescence intensitydistributions(FL1)from
artificial mixtures of A1 and A2 RBCs containing either: (a) 0%, (b) 50%, (c) 75%, or (d) 100% A1 cells. Genotype is defined as follows: ‘A1’ 5 202C
(wild-type), ‘A2’ 5 202T (deficient).
www.nature.com/scientificreports
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enzyme itself to confound assay results. Another known complica-
tion in interpreting the results of the MRT concerns cell-cell inter-
action
20,22,specificallythefindingthatsolublefactorscantrafficfrom
G6PD1 to G6PD- cells, possibly confounding results in mosaic
females, such as the one A1/2 outlier in our data who appeared
as a G6PD-normal homozygote by cytofluorometry.
Overall, in spite of the aforementioned concerns, assay perform-
ance was found to be robust and reliable, giving consistent results
across repeated measurements. Although the focus here was on a
high-throughput application of the method using flow cytometry,
the technique may be adaptable to additional applications. One
direct use for investigators interested in methemoglobinemia would
betodetectmethemoglobininanindividualRBCbysimplyusingthe
assayindependentlyoftheG6PDactivity-dependent MRTstep.Asa
screeningtoolforG6PDdeficiency,oneneedonlyhaveamicroscope
outfitted with a UV lamp to detect G6PD1 and G6PD- cells in a
blood sample, with no special fixation or staining procedures
required and at a low cost per assay. This may be especially well-
suited to areas such as Southeast Asia and Oceania where there is
considerable allelic heterogeneity
35 that makes genotyping cost inef-
fective. Finally, if the ultimate goal is to understand how genetic
variation at G6PD influences an individual’s complex, multifactorial
response to primaquine administration or to Plasmodium infection,
methodslikethatdescribedherewillbecriticalinfurtherelucidating
the proximate relationship between genotype and molecular pheno-
types.
Methods
Samples. Peripheral blood samples from 42 children aged 1–15 years (mean 5 5.8
years) werecollected at a rural health center in Kenieroba, Mali. Of these children, 22
were male and 20 were female, and most (79%) children were of Malinke ethnicity.
Figure 3 | DemonstrationofthecytofluorometricmethodonRBCsfromA1,A1/2,andA2individuals. Shownherearerepresentativefluorescence
intensity distributions (FL1) and fluorescence micrographs from A1 (top), A1/2 (middle), and A2 (bottom) individuals. Genotype is defined as
follows: ‘A1’ 5 202C (wild-type), ‘A1/2’ 5 202CT (heterozygous), ‘A2’ 5 202T (deficient). The estimated proportion of high (blue) and low (red)
intensity cells for each individual is indicated. NB:The micrographs show two populations of RBCs, one that is bright (G6PD1) andanother that isdim
(G6PD-).
www.nature.com/scientificreports
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202.Bloodwasobtainedbyvenipuncture,anticoagulated usingacid-citrate-dextrose,
washedthreetimesinRPMI1640priortostorageat4uC,andprocessedwithin4days.
All samples were obtained with parental informed consent and under protocols
approved by the Ethics Committee of the Faculty of Medicine, Pharmacy and
Odontostomatology atthe University ofBamako,and the InstitutionalReview Board
of the National Institute of Allergy and Infectious Diseases.
Genotyping. Genotyping of the G6PD 202 polymorphism was performed by
restriction fragment length polymorphism (RFLP) analysis using a nested PCR
protocol, as described previously
37.
Gross G6PD activity assay. Gross G6PD activity was measured in duplicate with the
G6PDH kit (PD-410, Randox Laboratories, Kearneysville, WV), using a modified
protocoladaptedfor high-throughput screening.First, a hemolysate waspreparedby
combining 10 ml of RBC suspension (50% hematocrit) with 20 ml of digitonin. Next,
2 ml of this hemolysate was combined with 4 ml NADP (0.34 mM), 2 ml glucose-6-
phosphate (0.58 mM), and 120 ml reaction buffer (triethanolamine 31.7 mM, EDTA
3.2 mM,pH7.6).ReactionratewasassessedusingaUV/VISplatespectrophotometer
byobservingtherateofproductionofNAPDH,whichabsorbslightat340 nm,overa
30 min time course. Reaction rate was normalized to total protein content by
measuring absorbance of hemoglobin at 540 nm, as follows:
G6PD activity~
DOD340
Dt
OD540
Methemoglobin reduction test. The methemoglobin reduction test was performed
induplicatebymodificationofpreviouslypublishedprotocols
19,20.Onehundredmlof
RBC suspension (5% hematocrit) was combined with 100 ml of sodium nitrite
(0.125 M,Sigma),andincubatedatroomtemperaturefor20 min.Sampleswerethen
washed three times with phosphate-buffered saline (PBS), with centrifugation at
1800 rpmfor1 min,andresuspendedto100mlwithPBS.Finally,thewashed,nitrite-
treatedRBCswerecombinedwith18mlofglucose(0.28 MinPBS,Sigma)and6mlof
Nile blue sulfate (0.01%, Sigma), and incubated at 37uC for 90 min in an aerobic
environment (i.e., in open microcentrifuge tubes).
Cytofluorometric method. At the completion of the methemoglobin reduction test,
2.5 ml of potassium cyanide (0.4 M, Sigma) was added to each sample, and incubated
at room temperature for 5 min. Five ml of each sample was then added to 100 mlo f
hydrogenperoxide(3%inPBS,Sigma),agitatedvigorouslybyhand,andthenwashed
two times in PBS, with centrifugation at 3000 rpm for 3 min.
Flow cytometry. Samples were analysed in duplicate using an Accuri C6 flow
cytometer,usingdefaultfactorysettings,with10,000totaleventsmeetingsizethreshold
ofFSC-H.80,000 collected.Sampleswereexcited usinganAr ion laser(488 nm) and
fluorescence emission was measured in the FL1 channel (533 6 30 nm).
Fluorescence microscopy. Wet mounts of RBC samples were prepared and imaged
onanOlympusBX53fluorescencemicroscopeusingthe40xoilimmersionobjective,
a100 WHgarclamp,andaFITCfiltercube.Allimagesweretakenusinga10-second
exposure time and processed identically using ImageJ (NIH, Bethesda, MD).
Dataanalysis.Customscripts(availableuponrequest)werewritteninRtoautomate
data analysis. Gross activity was calculated using the formula above, with coefficients
derived from linear modeling functions. Flow cytometry data were first converted
from FCS format to raw data using the ‘flowCore’ package
38, and then subject to
morphological gating, with events retained only if they lay in the central 95% of the
empirical distribution for both forward scatter (FSC) and side scatter (SSC)
parameters.Next,theFL1fluorescence intensitydistributionwasanalysed toidentify
and quantify high and low intensity subpopulations. First, maxima in the kernel
density estimation function were identified, and then the midpoint between the two
maxima was used as an ad hoc gate between high and low intensity subpopulations
(Figure1,rightpanel). Whenonlyonemaximumwasfound (i.e., forG6PD-deficient
homozygotes), the ad hoc gate was placed 0.5 log units away (about half the average
distance between high and low intensity subpopulations in our dataset).
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